Why START? Reflections that led to the conduct of this large long-term strategic HIV trial

HIV Medicine

Volumn 16, Issue S1, 2015, Pages 1-9

  Lundgren, Jens ^a   Babiker, Abdel ^b   Gordin, Fred ^c   Emery, Sean ^d   Fätkenheuer, Gerd ^e   Molina, Jean Michel ^f   Wood, Robin ^g,h   Neaton, James D ⁱ   Agan, Brian K ^j   Alston Smith, Beverly ^j   Arenas Pinto, Alejandro ^j   Arribas, Jose R ^j   Baker, Jason V ^j   Baxter, John ^j   Belloso, Waldo H ^j   Brekke, Kate ^j   Brew, Bruce ^j   Brobst, Susan W ^j   Burman, William ^j   Carey, Cate ^j   Clark, Richard ^j   Cooper, David A ^j   Davey, Richard T ^j   De La Rosa, Guy ^j   Denning, Eileen T ^j   Dolan, Matthew ^j   Dore, Gregory ^j   Duprez, Daniel ^j   Emanuel, Ezekiel ^j   Grady, Christine ^j   Grund, Birgit ^j   Hirschel, Bernard ^j   Hoen, Bruno ^j   Hudson, Fleur ^j   Johnson, Margaret A ^j   Kambili, Chrispin ^j   Klingman, Karin ^j   Kunisaki, Ken M ^j   Landay, Alan ^j   Ledergerber, Bruno ^j   Lehrman, Sandra N ^j   Martinez, Ana ^j   Meger, Sue ^j   Misar, Kelly ^j   Mitsuyasu, Ronald T ^j   Mocroft, Amanda ^j   Munroe, David ^j   Norton, Michael ^j   Palmer, Robert C ^j   Pett, Sarah L ^j   Phillips, Andrew ^j   Pillay, Deenan ^j   Porter, Danielle ^j   Price, Richard W ^j   Proschan, Michael ^j   Rappoport, Claire ^j   Reiss, Peter ^j   Renjifo, Boris ^j   Robertson, Kevin ^j   Rockstroh, Jürgen ^j   Rodriguez, Gabriela ^j   Rooney, James F ^j   Ross, Michael J ^j   Schechter, Mauro ^j   Schwarze, Siegfried ^j   Seekins, Daniel ^j   Sharma, Shweta ^j   Snowden, Wendy ^j   Telenti, Amalio ^j   Tryon, Jeff ^j   van Wyk, Jean ^j   Vjecha, Michael J ^j   Wright, Edwina ^j   more..

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d Kirkby Institute   (Australia)

^e UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g UNIVERSITY OF CAPE TOWN   (South Africa)

^h LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

ⁱ UNIVERSITY OF MINNESOTA   (United States)

^j NONE

more..

Author keywords

Antiretroviral therapy; CD4 guided ART; HIV; START trial; When to start

Indexed keywords

INTERLEUKIN 6; ANTIRETROVIRUS AGENT;

BONE DENSITY; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; DRUG INDUSTRY; DUAL ENERGY X RAY ABSORPTIOMETRY; EDITORIAL; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; LIVER FIBROSIS; LONG TERM CARE; MORBIDITY; MORTALITY; OBSERVATIONAL STUDY; PILOT STUDY; PRIORITY JOURNAL; RISK FACTOR; TASK PERFORMANCE; VISUAL ANALOG SCALE; ADULT; COHORT ANALYSIS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; IMMUNOLOGY; MALE; PATHOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); TIME FACTOR; TREATMENT OUTCOME;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 84923323284     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12227     Document Type: Editorial

References (41)

1. Emery S, Neuhaus JA, Phillips AN etal. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008; 197: 1133-1144.
2. Severe P, Juste MA, Ambroise A etal. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 2010; 363: 257-265.
3. Grinsztejn B, Hosseinipour MC, Ribaudo HJ etal. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis 2014; 14: 281-290.
4. Kitahata MM, Gange SJ, Abraham AG etal. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360: 1815-1826.
5. Sterne JA, May M, Costagliola D etal. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373: 1352-1363.
6. CASCADE Collaboration. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. Arch Intern Med 2011; 171: 1560-1569.
7. Cain LE, Logan R, Robins JM etal. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med 2011; 154: 509-515.
8. Sabin CA, Cooper DA, Collins S, Schechter M. Rating evidence in treatment guidelines: a case example of when to initiate combination antiretroviral therapy (cART) in HIV-positive asymptomatic persons. AIDS 2013; 27: 1839-1846.
9. Lundgren JD, Babiker AG, Gordin FM, Borges ÁH, Neaton JD. When to start antiretroviral therapy: the need for an evidence base during early HIV infection. BMC Med 2013; 11: 148.
10. Franco RA, Saag MS. When to start antiretroviral therapy: as soon as possible. BMC Med 2013; 11: 147.
11. El-Sadr WM, Lundgren J, Neaton JD etal. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283-2296.
12. El-Sadr WM, Grund B, Neuhaus J etal. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med 2008; 149: 289-299.
13. Lundgren JD, Babiker A, El-Sadr W etal. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. J Infect Dis 2008; 197: 1145-1155.
14. Pant Pai N, Tulsky JP, Lawrence J, Colford JM, Reingold AL. Structured treatment interruptions (STI) in chronic suppressed HIV infection in adults. Cochrane Database Syst Rev 2005; (4): CD005482.
15. Neaton JD, Babiker A, Bohnhorst M etal. Regulatory impediments jeopardizing the conduct of clinical trials in Europe funded by the National Institutes of Health. Clin Trials 2010; 7: 705-718.
16. Cohen MS, Chen YQ, McCauley M etal. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365: 493-505.
17. Kuller LH, Tracy R, Belloso W etal. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5: e203.
18. Duprez DA, Neuhaus J, Kuller LH etal. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS ONE 2012; 7: e44454.
19. th Conference on Retroviruses and Opportunistic Infections. Atlanta, USA, March 2013.
20. Borges ÁH, Silverberg MJ, Wentworth D etal. Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers. AIDS 2013; 27: 1433-1441.
21. Nordell AD, McKenna M, Borges ÁH etal. Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation. J Am Heart Assoc 2014; 3: e000844.
22. Borges AH, Weitz JI, Collins G etal. Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease. AIDS 2014; 28: 1791-1796.
23. Boulware DR, Hullsiek KH, Puronen CE etal. Higher levels of CRP, d-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis 2011; 203: 1637-1646.
24. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium, Hingorani AD, Casas JP. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 2012; 379: 1214-1224.
25. Ridker PM, Luscher T. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J 2014; 35: 1782-1791.
26. Babiker AG, Emery S, Fätkenheuer G etal. Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clin Trials 2013; 10 (1 Suppl): S5-S36.
27. Geffen N, Aagaard P, Corbelli GM etal. Community perspective on the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015; 16 (Suppl 1): 10-13.
28. Grarup J, Rappoport C, Engen NW etal. Challenges, successes and patterns of enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015; 16 (Suppl 1): 14-23.
29. Denning E, Sharma S, Smolskis M etal. Reported consent processes and demographics: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015; 16 (Suppl 1): 24-29.
30. Sharma S, Babiker AG, Emery S etal. Demographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015; 16 (Suppl 1): 30-36.
31. Law MG, Achhra A, Deeks SG etal. Clinical and demographic factors associated with low viral load in early untreated HIV infection in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015; 16 (Suppl 1): 37-45.
32. Soliman EZ, Sharma S, Arastéh K etal. Baseline cardiovascular risk in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015; 16 (Suppl 1): 46-54.
33. Achhra AC, Mocroft A, Ross MJ etal. Kidney disease in antiretroviral-naïve HIV-positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015; 16 (Suppl 1): 55-63.
34. Rodger AJ, Lampe FC, Grulich AE etal. Transmission risk behaviour at enrolment in participants in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015; 16 (Suppl 1): 64-76.
35. Baxter JD, Dunn D, White E etal. Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015; 16 (Suppl 1): 77-87.
36. Lifson AR, Grandits GA, Gardner EM etal. Quality of life assessment among HIV-positive persons entering the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015; 16 (Suppl 1): 88-96.
37. Wright EJ, Grund B, Cysique LA etal. Factors associated with neurocognitive test performance at baseline: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015; 16 (Suppl 1): 97-108.
38. Baker JV, Engen NW, Huppler Hullsiek K etal. Assessment of arterial elasticity among HIV-positive participants with high CD4 cell counts: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015; 16 (Suppl 1): 109-118.
39. Kunisaki KM, Niewoehner DE, Collins G etal. Pulmonary function in an international sample of HIV-positive, treatment-naïve adults with CD4 counts > 500 cells/μL: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015; 16 (Suppl 1): 119-128.
40. Matthews GV, Neuhaus J, Bhagani S etal. Baseline prevalence and predictors of liver fibrosis among HIV-positive individuals: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015; 16 (Suppl 1): 129-136.
41. Carr A, Grund B, Neuhaus J etal. Prevalence of and risk factors for low bone mineral density in untreated HIV infection: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015; 16 (Suppl 1): 137-146.